Solid Forms Of A Transthyretin Dissociation Inhibitor

Abstract

The present invention relates to solid forms of the N-methyl-D-glucamine (meglumine) salt of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole and to methods for their preparation. The invention is also directed to pharmaceutical compositions containing at least one solid form and to the therapeutic or prophylactic use of such solid forms and compositions.

1 - 6 . (canceled) 
     
     
         7 . A crystalline form of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole meglumine, wherein said crystalline form has a solid state NMR spectrum comprising  13 C chemical shifts (ppm) at 112.6±0.2, 133.9±0.2, and 171.5±0.2. 
     
     
         8 . (canceled) 
     
     
         9 . (canceled) 
     
     
         10 . The crystalline form of  claim 7 , wherein said form is non-hygroscopic and anhydrous. 
     
     
         11 . The crystalline form of  claim 7 , wherein said form is substantially pure. 
     
     
         12 . A pharmaceutical composition comprising the crystalline form of  claim 7 . 
     
     
         13 . A method of treating transthyretin amyloid disease in a mammal, the method comprising administering to the mammal a therapeutically effective amount of the crystalline form of  claim 7 . 
     
     
         14 . The crystalline form of  claim 7 , wherein said form comprises a plurality of small crystallites of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole meglumine. 
     
     
         15 . The crystalline form of  claim 7 , wherein said form comprises a plurality of needle shaped crystals of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole meglumine.